Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ultragenyx Pharmaceutical Inc.
  6. News
  7. Summary
    RARE   US90400D1081

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  05/24 04:00:00 pm EDT
45.80 USD   -4.46%
05/24Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Keeps Neutral Rating
MT
05/19Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reiterates Overweight Rating
MT
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx Pharmaceutical : Says Crysvita Wins Canada Approval for Second Indication for Endocrine Disorder

09/07/2021 | 09:58am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about ULTRAGENYX PHARMACEUTICAL INC.
05/24Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Kee..
MT
05/19Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reit..
MT
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
GL
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
AQ
05/19Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two ..
CI
05/17Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Ther..
MT
05/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
AQ
05/10TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Co..
CI
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 373 M - -
Net income 2022 -512 M - -
Net cash 2022 437 M - -
P/E ratio 2022 -6,29x
Yield 2022 -
Capitalization 3 203 M 3 203 M -
EV / Sales 2022 7,41x
EV / Sales 2023 5,81x
Nbr of Employees 1 119
Free-Float 95,6%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 45,80 $
Average target price 125,44 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-45.53%3 352
GILEAD SCIENCES, INC.-11.38%79 850
REGENERON PHARMACEUTICALS, INC.8.63%73 473
VERTEX PHARMACEUTICALS22.26%68 632
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666